Though your question was rhetorical, for those that need help: For the same reason they never provided a Rett RSBQ AUC chart, as it would show the drugged arm week-12 data point reverting back toward placebo. In the AD OLE, the possibilities are:
- The week 144 and 192 data points don't show a distinct flattening trend
- Missling bumbled
Hopefully it's the latter. The helpless will say they didn't have time. Biotech's not for everyone?.
I hope we get charts at AD/PD, or before. Not likely. We never got RSBQ AUC charts, or ADL Odds Risk support data. We did get an ADL chart, but only after the company changed tack via the new guidelines. In science, transparency is always best. The company should have shown the OLE charts (along with the supportable delayed-start argument), and emphasized the safety and tolerability focus of OLEs.
Market Data 
Markets 
AI
